the health
transformation
knowledge portal
Joaquim Cardoso MSc
Founder and Chief Researcher, Editor & Strategist
March 14, 2024
What is the message?
Groundbreaking research led by the University College Dublin (UCD) is leveraging artificial intelligence (AI) to revolutionize the diagnosis of pre-eclampsia, a condition affecting millions of pregnant women globally.
This innovative approach promises to save tens of thousands of lives by providing clinicians with effective and efficient diagnostic tools.
This summary is based on the article “Groundbreaking pre-eclampsia research could save tens of thousands of lives”, published by SAS.
What are the key points?
Pre-eclampsia Impact: Pre-eclampsia affects over 11 million women and their babies worldwide annually, leading to 70,000 maternal deaths and 500,000 infant deaths each year.
AI_PREMie Initiative: UCD’s AI_PREMie initiative aims to transform pre-eclampsia diagnosis through intelligent risk stratification using AI algorithms, enhancing health outcomes for women and infants.
Partnership with SAS and Microsoft: UCD collaborates with SAS and Microsoft to develop and deploy AI_PREMie, ensuring scalability, data security, and interoperability with existing hospital systems.
Clinical Decision Support: AI_PREMie provides clinicians with a risk score and flags to aid clinical decision-making, integrating platelet biomarkers and other clinical data.
Clinical Trial Progress: The project has recruited 500 pregnant women across Dublin maternity hospitals, showing promising results and aiming for global deployment in the near future.
What are the key statistics?
1 in 12 pregnancies worldwide are affected by pre-eclampsia.
Pre-eclampsia complications lead to over 5 million premature births annually.
Every seven minutes, a pregnant woman loses her life due to pre-eclampsia complications.
What are the key examples?
UCD’s partnership with SAS and Microsoft ensures the development of a robust AI-powered diagnostic tool, offering interoperability and scalability.
AI_PREMie’s initial trials in Dublin maternity hospitals demonstrate its potential to prevent maternal and infant deaths caused by pre-eclampsia.
Conclusion
UCD’s groundbreaking research, supported by SAS and Microsoft, heralds a new era in pre-eclampsia diagnosis.
By leveraging AI, AI_PREMie aims to provide clinicians worldwide with the tools they need to save lives and prevent medical complications associated with pre-eclampsia.
To read the original publication, click here.
